BRPI0415743A - fator viii viralmente segurizado com baixo teor em multìmeros superiores - Google Patents

fator viii viralmente segurizado com baixo teor em multìmeros superiores

Info

Publication number
BRPI0415743A
BRPI0415743A BRPI0415743-5A BRPI0415743A BRPI0415743A BR PI0415743 A BRPI0415743 A BR PI0415743A BR PI0415743 A BRPI0415743 A BR PI0415743A BR PI0415743 A BRPI0415743 A BR PI0415743A
Authority
BR
Brazil
Prior art keywords
virally
factor viii
insured
factor
higher multimer
Prior art date
Application number
BRPI0415743-5A
Other languages
English (en)
Inventor
Abdessatar Chtourou
Michel Nogre
Roland Schmitthaeusler
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0415743A publication Critical patent/BRPI0415743A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

"FATOR VIII VIRALMENTE SEGURIZADO COM BAIXO TEOR EM MULTìMEROS SUPERIORES". A presente invenção refere-se a uma composição de Fator VIII de origem plasmática securizado viralmente, obtida após filtragem nanométrica, compreendendo o Fator von Willebrand (FvW) a uma taxa inferior ou igual a 15 % dos decâmeros e multímeros superiores. Essas composições apresentam um fator de redução do título dos vírus superior a 4 log e são portanto adaptadas para o tratamento da hemofilia.
BRPI0415743-5A 2003-10-23 2004-10-25 fator viii viralmente segurizado com baixo teor em multìmeros superiores BRPI0415743A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312398A FR2861395B1 (fr) 2003-10-23 2003-10-23 Facteur viii viralement securise a faible teneur en multimeres superieurs
PCT/FR2004/002737 WO2005040214A1 (fr) 2003-10-23 2004-10-25 Facteur viii viralement securise a faible teneur en multimeres superieurs

Publications (1)

Publication Number Publication Date
BRPI0415743A true BRPI0415743A (pt) 2006-12-19

Family

ID=34400721

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415743-5A BRPI0415743A (pt) 2003-10-23 2004-10-25 fator viii viralmente segurizado com baixo teor em multìmeros superiores

Country Status (12)

Country Link
US (1) US7932355B2 (pt)
EP (3) EP2108659A1 (pt)
JP (2) JP4872669B2 (pt)
AT (1) ATE452911T1 (pt)
AU (1) AU2004283931B2 (pt)
BR (1) BRPI0415743A (pt)
CA (1) CA2543095C (pt)
DE (1) DE602004024812D1 (pt)
ES (1) ES2335893T3 (pt)
FR (1) FR2861395B1 (pt)
IL (3) IL175027A (pt)
WO (1) WO2005040214A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
HRP20110927T1 (hr) * 2007-12-28 2012-02-29 Baxter International Inc. Protutlačna filtracija proteina
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
JP5711369B2 (ja) * 2011-06-24 2015-04-30 旭化成メディカル株式会社 蛋白製剤の製造方法
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
CN104804078B (zh) * 2015-05-05 2019-01-04 广东卫伦生物制药有限公司 人体血清凝血因子ⅷ中的病毒过滤方法
KR20250088663A (ko) 2017-08-23 2025-06-17 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
US20200376444A1 (en) * 2018-02-19 2020-12-03 Bayer Heal Thcare Llc Modified Filter Membrane and Method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5522991A (en) 1994-07-20 1996-06-04 Millipore Investment Holdings Limited Cellulosic ultrafiltration membrane
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.

Also Published As

Publication number Publication date
IL228278A (en) 2015-07-30
IL175027A (en) 2013-10-31
CA2543095A1 (fr) 2005-05-06
US7932355B2 (en) 2011-04-26
JP4872669B2 (ja) 2012-02-08
IL175027A0 (en) 2006-08-20
IL228277A (en) 2015-07-30
EP1675872A1 (fr) 2006-07-05
US20070275880A1 (en) 2007-11-29
AU2004283931B2 (en) 2010-08-26
EP2108659A1 (fr) 2009-10-14
ATE452911T1 (de) 2010-01-15
DE602004024812D1 (de) 2010-02-04
CA2543095C (fr) 2017-07-11
EP1675872B1 (fr) 2009-12-23
FR2861395A1 (fr) 2005-04-29
WO2005040214A1 (fr) 2005-05-06
JP2011252016A (ja) 2011-12-15
ES2335893T3 (es) 2010-04-06
EP2805968A1 (fr) 2014-11-26
AU2004283931A1 (en) 2005-05-06
FR2861395B1 (fr) 2006-02-17
JP2007535487A (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
BRPI0415743A (pt) fator viii viralmente segurizado com baixo teor em multìmeros superiores
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BR9803109A (pt) N,n',n"'- tris({2,4-bis[(1-hidroxicarbilóxi-2,2,6,6-tetrametilpipe ridin-4-il)alquilamino]-s-triazin-6-il}3,3'-etilenodiimin odipropilaminas, seus usÈmeros e derivados ligados por ponte e composições de polìmero estabilizadas com as mesmas.
EP1590336A4 (en) SUBSTITUTED PYRAZOLE, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND APPLICATION METHOD
TR200200763T2 (tr) Antiviral bileşimler
ATE549028T1 (de) Stabile analoga von glp-1
PL373374A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
TR199801225T2 (xx) Geli�tirilmi� biyolojik kullan�l�rl��a sahip antifungal bile�imler.
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
BR112014012199A2 (pt) composição de oligômeros siloxanos olefinicamente funcionalizados à base de alcoxisilanos
NO20053545L (no) Bindingsmidler som inhiberer myostatin.
WO2014011819A3 (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof
BR9902268A (pt) Formulações de ziprasidona.
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
ATE404544T1 (de) Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
AU2003228674A1 (en) Muscarinic antagonists
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
CY1114532T1 (el) (2r)-2-[(4-σουλφονυλ)αμινοφαινυλ]προπαναμιδια και φαρμακευτικες συνθεσεις περιεχοντας τα
DE60323942D1 (de) Lipase-hemmende zusammensetzung
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
DE60213402D1 (de) Neue polynukleotide und polypeptide des ifn alpha-17-gens

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements